YOLFTbeta
Satellos Bioscience Inc.

Satellos Bioscience Inc.

MSCL · TO · Healthcare / Biotechnology

9.50CAD-0.07 (-0.73%)

Price History

Full chart

Market Stats

Previous Close9.57
Open10.24
Day Range9.28 – 10.24
52-Week Range7.56 – 18.98
Volume6.39K
Market Cap243.99M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.70
Dividend Yield0.00%
Beta1.15
50-Day Avg13.18
200-Day Avg11.64

About

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Francis Gleeson B.B.A. M.B.A
  • Employees18
  • HeadquartersRoyal Bank Plaza, Toronto, ON, Canada, M5J 2J1, Canada
  • Websitehttps://satellos.com

Leadership

  • Mr. Francis Gleeson B.B.A. M.B.ACo-Founder, CEO, President & Director · b. 1955
  • Ms. Elizabeth Williams C.A., CPACFO & Corporate Secretary · b. 1978
  • Dr. Philip Lambert M.A., Ph.D.Chief Scientific Officer · b. 1969
  • Dr. Wildon Farwell M.D., M.P.H.Chief Medical Officer · b. 1976
  • Dr. Michael A. Rudnicki Ph.D.Co-Founder & Chief Discovery Officer · b. 1962
  • Mr. J. Robert Hall CFASenior Vice President of Finance & Administration
  • Dr. Ryan Mitchell Ph.D.Senior VP & Head of Corporate Development
  • Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A.Strategic Advisor · b. 1960
  • Mr. Warren Whitehead C.M.A., C.P.A.Head of Corporate Strategy · b. 1952
  • Ms. Desiree ChanChief of Staff

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---99.88K--------25.00K-00000
Cost of Revenue--470.03K-109.23K87.79K87.10K49.73K22.01K27.40K23.48K1.54K3.06K422165.69K3.73M7.00K20.00K5.09K
Gross Profit---470.03K--109.23K-87.79K-87.10K-49.73K-22.01K-27.40K-23.48K-1.54K-3.06K-422-165.69K-3.73M-8.82M-20.00K-5.09K
Gross Margin-------------12.25%------
Operating Expense--1.80M-2.36M3.57M6.05M2.21M2.19M1.20M1.45M2.20M2.20M2.77M6.48M4.69M6.65M27.79M26.92M
Operating Income-5.16M-2.73M-2.27M-3.10M-2.47M-3.66M-6.14M-2.26M-2.21M-1.23M-1.47M-2.20M-2.21M-2.77M-6.65M-8.43M-15.46M-27.81M-26.92M
Operating Margin----3106.26%---------8822.69%------
EBITDA-5.05M-2.62M-2.15M-2.99M-2.36M-3.57M-6.05M-2.21M-2.19M-1.20M-1.45M-2.20M-2.00M-1.61M-4.69M-8.09M-15.71M-28.08M-26.92M
EBITDA Margin----2995.71%---------7995.23%------
Net Income-5.18M-2.76M-2.30M-3.10M-1.03M-3.64M-5.67M-2.01M-1.80M-1.49M-1.24M-1.70M-1.94M-1.58M-15.51M-11.32M-15.89M-28.10M-25.31M
Net Income Margin----3104.65%---------7752.94%------
R&D3.71M1.43M1.13M1.66M1.03M2.20M3.99M622.50K627.35K564.22K786.63K1.42M917.48K892.78K1.88M2.59M8.82M19.60M18.75M
R&D as % of Total Revenue---1664.30%--------3669.90%------
Interest Expense-------------23.05K985.33K50.91K177.00K0-

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.27M1.48M4.62M2.68M2.94M3.01M3.93M7.09M3.90M2.45M1.37M178.14K1.07M1.13M12.59M6.20M44.30M73.02M31.83M
Total Liabilities782.60K446.15K321.96K291.36K255.01K963.55K2.63M1.58M115.22K138.13K288.16K802.53K664.81K1.31M2.10M2.83M3.62M5.16M4.10M
Total Equity2.49M1.03M4.29M2.38M2.69M2.05M1.30M5.51M3.78M2.31M1.09M-624.38K408.57K-183.84K10.48M3.37M40.67M67.86M27.73M
Cash1.89M624.97K1.38M631.58K255.42K599.34K1.11M3.70M2.73M2.36M1.13M10.14K399.13K717.53K4.87M1.92M22.07M57.66M9.79M
Total Debt-------------1.09M-----
Net Debt-1.89M-624.97K-1.38M-631.58K-255.42K-599.34K-1.11M-3.70M-2.73M-2.36M-1.13M-10.14K-399.13K375.78K-4.87M-1.92M-22.07M-57.66M-9.79M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.91M-2.40M-2.12M-2.67M-1.93M-2.76M-3.77M-2.84M-3.10M-1.33M-1.10M-1.92M-1.66M-5.03M-5.64M-14.42M-24.98M-24.01M
Investing Cash Flow586.63K24.28K-2.51M1.09M514.43K407.06K-138.17K-890.31K2.00M-4.03K-3.19K-771-1.74M-3.00K-17.54M6.34M-9.58M
Financing Cash Flow4.25M1.10M5.39M820.11K1.04M2.69M4.43M6.28M---1.16M1.98M7.45M2.77M51.03M53.48M2.28M
Capital Expenditure10.93K18.20K3.06K6.83K2.10K2.97K401.86K4.03K3.19K77107.25K3.00K18.00K6.00K6.10K
Free Cash Flow-3.92M-2.42M-2.12M-2.67M-1.94M-2.76M-3.77M-2.84M-3.10M-1.34M-1.11M-1.93M-1.66M-5.04M-5.79M-14.52M-24.98M-24.02M
Dividends Paid--------------00--
FCF to OCF100.28%100.76%100.14%100.26%100.11%100.11%100.00%100.00%100.06%100.30%100.29%100.04%100.00%100.14%102.53%100.71%100.02%100.03%
Dividend Paid to FCF--------------0.00%0.00%--

Earnings

Report DateMar 27, 2024May 14, 2024Aug 12, 2024Nov 13, 2024Mar 26, 2025May 13, 2025Aug 13, 2025Nov 14, 2025Mar 27, 2026May 13, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.01-0.60-0.60-0.48-0.60-0.60-0.60-0.66-0.50-0.59-0.51-0.62
EPS Actual-0.07-0.72-0.60-0.96-0.72-0.67-0.50-0.50-0.69-0.73-0.78-
Surprise-600.00%-20.00%0.00%-100.00%-20.00%-11.67%16.67%24.24%-38.00%-23.63%-52.94%-
TimingPre-marketAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap243.99M
Enterprise Value171.21M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.07
EPS-2.70
Book Value4.10
Revenue (TTM)0
Gross Profit (TTM)-9.48M
EBITDA-35.82M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-70.45%
Return on Assets-41.89%
Shares Outstanding21.22M
Shares Float18.02M
Beta1.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 30, 20261:12
  • Aug 18, 20211:20